Topiramate

**Topiramate** is a novel, second-generation **anticonvulsant** medication primarily used as an add-on (adjunctive) therapy for refractory seizure disorders in dogs and cats. * **Clinical Utility**: It is particularly useful for managing **partial (focal) seizures** and automatisms (e.g., "running fits" in cats). * **Pharmacokinetic Profile**: It has a remarkably short half-life in dogs (2-4 hours), but its high affinity for brain receptors allows for sustained therapeutic activity despite rapid clearance. * **Role in Therapy**: Often considered when traditional first-line therapies (like phenobarbital, potassium bromide, or levetiracetam) are insufficient to achieve seizure control. * **Practical Considerations**: Generics are available, which helps mitigate costs, though the frequent dosing schedule (often TID in dogs) requires significant owner commitment.

Mechanism: Topiramate has a multimodal mechanism of action that dampens excitatory pathways and enhances inhibitory neurotransmission in the central nervous system: * **Voltage-gated Sodium Channels** → Blocks repetitive action potentials in a time-dependent manner, preventing the spread of seizure activity. * **GABA Receptors** → Increases the frequency of **GABA** activation at **GABA_A receptors**, enhancing inhibitory signals in the brain. * **AMPA/Kainate Receptors** → Antagonizes these specific glutamate receptors, directly blocking excitatory neurotransmission (without affecting NMDA receptors). * **Carbonic Anhydrase** → Weakly inhibits isoenzymes **CA-II** and **CA-IV**, though this is believed to play only a minor role in its overall antiepileptic efficacy.

VetSheet drug reference is intended for licensed veterinary professionals as a clinical decision-support aid, not a substitute for professional judgement or the manufacturer’s current label.